Aurinia Pharmaceuticals Inc. (AUPH) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Edmonton, BC, 캐나다. 현재 CEO는 Kevin C. Tang.
AUPH 을(를) 보유 IPO 날짜 2014-09-03, 130 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $2.14B.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
